The top 100 most frequently cited publications concerning anti-PD-1/PD-L1 therapy for lung cancer: A bibliometric analysis
Y Li, M Lv, J Liu, J Ma, M Liang… - Cancer management and …, 2021 - Taylor & Francis
Background Globally lung cancer is one of the most common cancers, and is responsible for
almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD …
almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD …
The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis
Y Li, M Lv, J Liu, J Ma, M Liang… - Cancer management …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Globally lung cancer is one of the most common cancers, and is responsible for
almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD …
almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD …
[PDF][PDF] The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis
Y Li, M Lv, J Liu, J Ma, M Liang… - Cancer Management …, 2021 - pdfs.semanticscholar.org
Background: Globally lung cancer is one of the most common cancers, and is responsible
for almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD …
for almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD …
The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis
L Yang, M Lv, J Liu, J Ma, M Liang… - Cancer Management …, 2021 - search.proquest.com
Background: Globally lung cancer is one of the most common cancers, and is responsible
for almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD …
for almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD …
The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis.
Y Li, M Lv, J Liu, J Ma, M Liang… - Cancer Management and …, 2021 - europepmc.org
Background Globally lung cancer is one of the most common cancers, and is responsible for
almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD …
almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD …
[HTML][HTML] The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis
Y Li, M Lv, J Liu, J Ma, M Liang… - Cancer Management and …, 2021 - ncbi.nlm.nih.gov
Background Globally lung cancer is one of the most common cancers, and is responsible for
almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD …
almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD …
The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis.
Y Li, M Lv, J Liu, J Ma, M Liang, N Zheng - Cancer Management and …, 2021 - go.gale.com
Background: Globally lung cancer is one of the most common cancers, and is responsible
for almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD …
for almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD …
The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis
Y Li, M Lv, J Liu, J Ma, M Liang… - Cancer Management and …, 2021 - dovepress.com
Background: Globally lung cancer is one of the most common cancers, and is responsible
for almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD …
for almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD …
The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis
Y Li, M Lv, J Liu, J Ma, M Liang… - Cancer management …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Globally lung cancer is one of the most common cancers, and is responsible for
almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD …
almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD …